



(51) International Patent Classification:

C07D 403/14 (2006.01) *A61K 31/506* (2006.01)
A61K 31/4178 (2006.01) *A61P 25/00* (2006.01)
A61K 31/4192 (2006.01)

(21) International Application Number:

PCT/IB2014/066548

(22) International Filing Date:

3 December 2014 (03.12.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/IB2013/060630

4 December 2013 (04.12.2013)

IB

(71) Applicant: ACTELION PHARMACEUTICALS LTD
[CH/CH]; Gewerbestrasse 16, CH-4123 Allschwil (CH).

(72) Inventors: **BOSS, Christoph**; c/o Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil (CH). **BRISBARE-ROCH, Catherine**; c/o Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil (CH). **BROTSCHI, Christine**; c/o Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil (CH). **GUDE, Markus**; Grabenring 9, CH-4123 Allschwil (CH). **HEIDMANN, Bibia**; c/o Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil (CH). **JENCK, Francois**; c/o Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil (CH). **SIFFERLEN, Thierry**; c/o Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil (CH). **STEINER, Michel**; c/o Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil (CH). **WILLIAMS, Jodi**; c/o Actelion Pharma-

ceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil (CH).

(74) Agent: **VELKER, Jörg**; c/o Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))

(54) Title: USE OF BENZIMIDAZOLE-PROLINE DERIVATIVES



Formula (I)

(57) Abstract: The present invention relates to compounds of the formula (I), wherein Ar¹ and Ar² are as described in the description and to their use as pharmaceuticals for the treatment of sundown syndrome. The invention also relates to the preparation of such compounds and of pharmaceutically acceptable salts thereof.